Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

OBJECTIVES: To evaluate the cost-effectiveness of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in basal–bolus regimens for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk based on the DEVOTE CV outcomes trial. METHODS: A microsimulation model,...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollock, Richard F., Valentine, William J., Marso, Steven P., Andersen, Andreas, Gundgaard, Jens, Hallén, Nino, Tutkunkardas, Deniz, Magnuson, Elizabeth A., Buse, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748892/
https://www.ncbi.nlm.nih.gov/pubmed/31264138
http://dx.doi.org/10.1007/s40258-019-00494-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748892/
https://www.ncbi.nlm.nih.gov/pubmed/31264138
http://dx.doi.org/10.1007/s40258-019-00494-3

Ejemplares similares